ClinicalTrials.gg
Active, not recruitingNCT04067336Updated May 13, 2026

First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia

A Phase 1/2 interventional study of Ziftomenib and Midazolam in Advanced Malignant Neoplasm, Acute Myeloid Leukemia and Mixed Lineage Leukemia, sponsored by Kura Oncology, Inc.. Active, not recruiting at 43 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-13.

Sponsored by Kura Oncology, Inc. · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
263
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 11 studies testing ziftomenib in Leukemia, Myeloid, Acute — 9 open to participants now, 11 under way, 1 of them phase 3. ziftomenib · Leukemia, Myeloid, Acute.

Planned enrollment
2nd of 11
263 · median 44
Started
2019
the only one that year
Phase 1/2
Only one
of the 11
Primary completion
2028-10
later than 7 of 10 live
Registered
1st of 11
by date
Lead sponsor
4 of 11
Kura Oncology, Inc.

Among the 11 studies testing ziftomenib in Leukemia, Myeloid, Acute, this one is the 2nd largest by planned enrollment, is the only one that started in 2019, is the only one in phase 1/2, reaches primary completion later than 7 of the 10 other live ones, and was the 1st registered.

Leukemia, Myeloid, Acute

3,669 studies on the registry are indexed under Leukemia, Myeloid, Acute; 816 are open to participants now.

Browse Leukemia, Myeloid, Acute studies →

Open to participants now

9 of the 11 studies testing ziftomenib in Leukemia, Myeloid, Acute are open now, in 12 countries. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 9 open studies →

About ziftomenib

ziftomenib: first FDA approval 2025 (KOMZIFTI). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 625 Leukemia, Myeloid, Acute studies recruiting now, 363 (58%) set no upper age limit and 222 (36%) stop at 75 or younger; 145 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies testing ziftomenib in Leukemia, Myeloid, Acute, or all of them as a file.
02

Study summary

In this trial, ziftomenib, a menin-MLL(KMT2A) inhibitor, will be tested in patients for the first time. The trial includes a Main Study and four sub-studies. In the Main Study (including Phase 1a, Phase 1b, and Phase 2 portions), ziftomenib will be evaluated in patients with relapsed or refractory (R/R) acute myeloid leukemia (AML). The main study has completed enrollment.

In Sub-studies 1 and 2, the effects of taking ziftomenib and other common drugs at the same time will be investigated in AML patients. In Sub-study 3, ziftomenib will be evaluated in patients with R/R acute lymphoblastic leukemia (ALL). In Sub-study 4, ziftomenib will be evaluated in patients with R/R AML with certain genetic mutations.

Read the detailed description

This first-in-human (FIH), open-label study will assess ziftomenib, a menin-MLL(KMT2A) inhibitor, in patients with relapsed or refractory (R/R) acute myeloid leukemia (AML). The trial includes a Main Study and four sub-studies.

The Main Study is a Phase 1/2 dose-escalation and dose-validation/expansion study to assess ziftomenib in patients with R/R AML. The dose-escalation part of the study (Phase 1a) will determine the maximum tolerated dose (MTD) and/or the recommended Phase 2 dose (RP2D). The dose-validation/expansion part of the study (Phase 1b) will determine the safety, tolerability, and minimal biologically effective dose (MBED) of ziftomenib in biomarker-specific dosing cohorts from among doses that demonstrated early biological activity and are determined to be safe in the dose-escalation phase. The Phase 2 portion of the study will determine the safety, tolerability, and anti-leukemia activity of ziftomenib in patients with nucleophosmin 1-mutant (NPM1-m) AML.

In Sub-study 1, the effects of co-administration of ziftomenib on the pharmacokinetics (PK) of midazolam will be studied in patients with R/R AML with certain genetic mutations.

In Sub-study 2, the effects of co-administration of itraconazole on the PK of ziftomenib will be studied in patients with R/R AML with certain genetic mutations.

In Sub-study 3, the safety, tolerability, and MBED/RP2D of ziftomenib will be studied in patients with R/R KMT2A-rearranged (KMT2A-r) ALL (Phase 1a dose escalation). These parameters will be investigated further for the RP2D in a Phase 1b dose-validation/cohort expansion part of the sub-study.

In Sub-study 4, the clinical activity of ziftomenib will be studied in patients with R/R AML with certain genetic mutations.

03

Conditions studied

  • Advanced Malignant Neoplasm
  • Acute Myeloid Leukemia
  • Mixed Lineage Leukemia
  • Mixed Lineage Acute Leukemia
  • Acute Leukemia of Ambiguous Lineage
  • Mixed Phenotype Acute Leukemia
  • Acute Lymphoblastic Leukemia

Keywords

  • AML
  • Hematological malignancy
  • KMT2A
  • NPM1
  • Menin
  • Leukemia
  • Acute Leukemia
  • ALL
  • MLL
  • Acute Lymphoblastic Leukemia
  • Acute Myeloid Leukemia
  • MEIS1
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

Patients with or relapsed AML defined as the reappearance of ≥ 5% blasts in the bone marrow and who have also failed or are ineligible for any approved standard of care therapies, including .

  1. Phase 1b:

    • Patients with a documented lysine[K]-specific methyltransferase 2-rearrangement (KMT2A-r), or
    • Patients with a documented nucleophosmin 1 mutation (NPM1-m)
  2. Phase 2:

    • Patients with a documented nucleophosmin 1 mutation (NPM1-m)
  3. Sub-studies:

    • Sub-studies 1 and 2: Patients with R/R AML with NPM1-m or other mutations associated with MEIS1 overexpression.
    • Sub-study 3: Patients with R/R Acute Lymphoblastic Leukemia (ALL) with KMT2A-r.
    • Sub-study 4: Patients with R/R AML with mutations associated with MEIS1 overexpression.
  4. ≥ 18 years of age.
  5. (ECOG) performance status of 0 to 2, and a of at least 2 months.
  6. Adequate liver and kidney function according to protocol requirements.
  7. Peripheral white blood cell (WBC) counts ≤ 30,000/μL. Patients may receive hydroxyurea to control and maintain white blood cell count prior to enrollment.
  8. Women of must be willing to use a highly effective method of throughout the study and for at least 187 days after the last dose of study treatment.
  9. Males with female partners of childbearing potential must agree to use a highly effective method of contraception throughout the study and for at least 97 days after the last dose of study treatment.

Key Exclusion Criteria:

  1. Diagnosis of acute promyelocytic leukemia.
  2. Diagnosis of chronic myelogenous leukemia in blast crisis.
  3. Donor lymphocyte infusion \< 30 days prior to study entry.
  4. Clinically active central nervous system (CNS) leukemia.
  5. Undergone HSCT and have not had adequate hematologic recovery.
  6. Receiving therapy post HSCT within 2 weeks of Cycle 1 Day 1.
  7. Grade ≥ 2 active (GVHD), moderate or severe limited chronic GVHD, or extensive chronic GVHD of any severity.
  8. Received chemotherapy immunotherapy, radiotherapy, or any ancillary therapy that is considered to be (i.e., used for non-approved indications(s) and in the context of a research investigation) \< 14 days prior to the first dose of ziftomenib or within 5 drug half-lives prior to the first dose of study drug.
  9. Not recovered to \< Grade 2 (National Cancer Institute v5.0) from all acute toxicities or deemed back to a stable baseline.
  10. Treatment with concomitant drugs that are strong inhibitors or inducers of cytochrome P450-isozyme 3A4 (), as follows:

    • Phase 1a, 1b, 2, and sub-studies 3 and 4: with the exception of antibiotics, antifungals, and antivirals that are used as standard of care or to prevent or treat infections and other such drugs that are considered absolutely essential for the care of the patient.
    • Sub-studies 1 and 2: No exceptions will be allowed except for the use of moderate CYP3A4 antifungal prophylaxis such as fluconazole or isavuconazole which is at steady state on Cycle 1 Day 1 and will continue through the completion of PKs on Cycle 1 Day 15 (for sub-study 1) or Cycle 1 Day 18 (for sub-study 2).
  11. Detectable viral load for , , or surface antigen indicative of active infection. Patients with controlled disease will not be excluded from study enrollment.
  12. Pre-existing disorder predisposing the patient to a serious or life-threatening infection (e.g. cystic fibrosis, congenital or acquired immunodeficiency, bleeding disorder, or cytopenias not related to AML).
  13. Active uncontrolled acute or chronic systemic fungal, bacterial, viral, or other infection.
  14. Significant cardiovascular disease including unstable angina pectoris, uncontrolled hypertension or arrhythmia, history of cerebrovascular accident including within the past 6 months, congestive heart failure ( Class III or IV) related to primary cardiac disease, ischemic or severe valvular heart disease, or a myocardial infarction within 6 months prior to the first dose of study treatment.
  15. Mean >480 ms on triplicate .
  16. Major surgery within 4 weeks prior to the first dose of study treatment.
  17. Women who are pregnant or lactating. All female patients with must have a negative serum pregnancy test within 72 hours prior to starting treatment.
  18. For sub-studies 1 and 2: Any intake of grapefruit, grapefruit juice, Seville oranges, Seville orange marmalade, or other products containing grapefruit or Seville oranges within 7 days of the first administration of ziftomenib until the end of Cycle 1.
  19. For sub-studies 1 and 2: Moderate ( class B) or severe (Child-Pugh class C) hepatic impairment.
Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
263 participants (estimated)

Study arms

  • Experimental
    Phase 1a - Dose Escalation

    AML patients will receive multiple doses of ziftomenib

    Drug: Ziftomenib

  • Experimental
    Phase 1b - Dose-Validation Expansion

    Cohort 1: KMT2A-r / NPM1-m R/R AML patients will receive ziftomenib Cohort 2: KMT2A-r / NPM1-m R/R AML patients will receive ziftomenib

    Drug: Ziftomenib

  • Experimental
    Phase 2

    NPM1-m R/R AML patients will receive the recommended phase 2 ziftomenib dose

    Drug: Ziftomenib

  • Experimental
    Sub-study 1

    R/R AML patients with mutations associated with MEIS1 overexpression will receive ziftomenib + midazolam

    Drug: Ziftomenib · Drug: Midazolam

  • Experimental
    Sub-study 2

    R/R AML patients with mutations associated with MEIS1 overexpression will receive ziftomenib + itraconazole

    Drug: Ziftomenib · Drug: Itraconazole

  • Experimental
    Sub-study 3

    Part 1a: KMT2A-r R/R ALL patients will receive multiple ziftomenib doses Part 1b: KMT2A-r R/R ALL patients will receive ziftomenib

    Drug: Ziftomenib

  • Experimental
    Sub-study 4

    R/R AML patients with mutations associated with MEIS1 overexpression will receive ziftomenib

    Drug: Ziftomenib

Interventions

  • Oral administration

    Also known as: KO-539

  • Oral administration

    Also known as: Seizalam, Hypnovel, Dormicum

  • Oral administration

    Also known as: Sporanox, Onmel, Tolsura

06

What researchers measure

Primary outcomes

  1. Phase 1a: Maximum tolerated dose (MTD) and/or the recommended Phase 2 dose (RP2D)

    MTD is defined as the highest dose that is not expected to cause dose limiting toxicity (DLT) in more than 20% of patients.

    Time frame: Dose Limiting Toxicities (DLTs) will be evaluated during the first 28 days (1 cycle)

  2. Phase 1b: Number of patients who experience Adverse Events (AEs) and Serious Adverse Events (SAEs)

    Assessed by NCI-CTCAE v5.0

    Time frame: During treatment and up to approximately 28 days after treatment discontinuation, or until immediately before the initiation of another anticancer therapy, whichever occurs first.

  3. Phase 1b: Minimum biologically effective dose

    Minimum biologically effective dose in dosing cohorts which have demonstrated biological activity and have been determined to be safe as a part of Part 1a

    Time frame: For at least 12 months following end of treatment

  4. Phase 1a, 1b, and 2: Evidence of anti-leukemia activity

    Assessed by the CR + CRh rate

    Time frame: For at least 12 months following end of treatment

  5. Sub-study 1: Time to observed maximum plasma concentration (Tmax) of ziftomenib and midazolam

    Tmax of ziftomenib, its metabolites, midazolam, and 1-hydroxymidazolam

    Time frame: Cycle 1 on Days 1 and 15 at predose and postdose

  6. Sub-study 1: Area under the plasma concentration-time curve from time 0 to time t (AUC0-t) of ziftomenib and midazolam

    AUC0-t of ziftomenib, its metabolites, midazolam, and 1-hydroxymidazolam

    Time frame: Cycle 1 on Days 1 and 15 at predose and postdose

  7. Sub-study 1: Maximum observed plasma concentration (Cmax) of ziftomenib and midazolam

    Cmax of ziftomenib, its metabolites, midazolam, and 1-hydroxymidazolam

    Time frame: Cycle 1 on Days 1 and 15 at predose and postdose

  8. Sub-study 2: Time to observed maximum plasma concentration (Tmax) of ziftomenib and itraconazole

    Tmax of ziftomenib, its metabolites, and itraconazole

    Time frame: Cycle 1 on Days 1, 15, and 22 at predose and postdose

  9. Sub-study 2: Area under the plasma concentration-time curve from time 0 to time t (AUC0-t) of ziftomenib and itraconazole

    AUC0-t of ziftomenib, its metabolites, and itraconazole

    Time frame: Cycle 1 on Days 1, 15, and 22 at predose and postdose

  10. Sub-study 2: Maximum observed plasma concentration (Cmax) of ziftomenib and itraconazole

    Cmax of ziftomenib, its metabolites, and itraconazole

    Time frame: Cycle 1 on Days 1, 15, and 22 at predose and postdose

  11. Sub-study 3: Minimum biologically effective dose (MBED) and/or the recommended Phase 2 dose (RP2D)

    Assessed by the number of patients that experience Adverse Events (AEs) and Serious Adverse Events (SAEs) per NCI-CTCAE v5.0

    Time frame: During treatment and up to approximately 28 days after treatment discontinuation, or until immediately before the initiation of another anticancer therapy, whichever occurs first

  12. Sub-study 3: Minimum biologically effective dose (MBED) and/or the recommended Phase 2 dose (RP2D)

    Assessed by CR

    Time frame: For at least 12 months following end of treatment

  13. Sub-study 3: Change in Eastern Cooperative Oncology Group (ECOG) status

    To assess the change in ECOG status

    Time frame: Timeframe: from Baseline to End of Treatment

  14. Sub-study 3: Time to observed maximum plasma concentration (Tmax) of ziftomenib

    Tmax of ziftomenib

    Time frame: Postdose on Cycle 1 Day 1 and Cycle 2 Day 1. Predose at Cycle 2 onwards

  15. Sub-study 3: Area under the plasma concentration-time curve from time 0 to time t (AUC0-t) of ziftomenib

    AUC0-t of ziftomenib

    Time frame: Postdose on Cycle 1 Day 1 and Cycle 2 Day 1. Predose at Cycle 2 onwards

  16. Sub-study 3: Maximum observed plasma concentration (Cmax) of ziftomenib

    Cmax of ziftomenib

    Time frame: Postdose on Cycle 1 Day 1 and Cycle 2 Day 1. Predose at Cycle 2 onwards.

  17. Sub-study 4: Complete remission (CR) and complete remission with partial hematologic recovery (CRh)

    To assess the CR+CRh rate

    Time frame: For at least 12 months following end of treatment

Secondary outcomes

  1. Phase 1a and 2: Number of patients that experience Adverse Events (AEs) and Serious Adverse Events (SAEs)

    Assessed by NCI-CTCAE v5.0

    Time frame: During treatment and up to approximately 28 days after treatment discontinuation, or until immediately before the initiation of another anticancer therapy, whichever occurs first.

  2. Phase 1a: Tmax

    Time to observed maximum plasma concentration of ziftomenib and/or its metabolites

    Time frame: Cycle 1 and Cycle 2. Each cycle is 28 days.

  3. Phase 1a: AUC(0-t)

    Area under the plasma concentration-time curve from time 0 to time t of ziftomenib and/or its metabolites

    Time frame: Cycle 1 and Cycle 2. Each cycle is 28 days.

  4. Phase 1a: Cmax

    Maximum plasma concentration of ziftomenib and/or its metabolites

    Time frame: Cycle 1 and Cycle 2. Each cycle is 28 days.

  5. Phases 1a, 1b, and 2: Complete remission (CR) and complete remission with partial hematologic recovery (CRh) measurable residual disease (MRD) negativity

    To assess the CR/CRh MRD negativity

    Time frame: For at least 12 months following discontinuation of treatment

  6. Phases 1a, 1b, and 2: Duration of response (DOR)

    To assess the DOR, defined as the duration of CR/CRh

    Time frame: For at least 12 months following discontinuation of treatment

  7. Phases 1a, 1b, and 2: Transfusion independence (TI)

    To assess transfusion independence

    Time frame: For at least 12 months following discontinuation of treatment

  8. Phases 1a, 1b, and 2: Overall response rate (ORR)

    To assess the ORR

    Time frame: For at least 12 months following discontinuation of treatment

  9. Phases 1a, 1b, and 2: Event-free survival (EFS)

    To assess event-free survival

    Time frame: For at least 12 months following end of treatment

  10. Phases 1a, 1b, and 2: Overall survival (OS)

    To assess overall survival

    Time frame: For at least 12 months following end of treatment

  11. Phases 1a, 1b, and 2: Composite complete remission (CRc)

    To assess CRc

    Time frame: For at least 12 months following discontinuation of treatment

  12. Phases 1b and 2: Composite complete remission (CRc) measurable residual disease (MRD) negativity

    To assess the CRc MRD negativity

    Time frame: For at least 12 months following discontinuation of treatment

  13. Phases 1b and 2: Overall response rate (ORR) measurable residual disease (MRD) negativity

    To assess the ORR MRD negativity

    Time frame: For at least 12 months following discontinuation of treatment

  14. Sub-study 2: Corrected QT (QTc) intervals

    Assessed by QTc intervals

    Time frame: During Cycle 1

  15. Sub-study 3: Complete remission (CR) measurable residual disease (MRD) negativity

    To assess the CR MRD negativity

    Time frame: For at least 12 months following discontinuation of treatment

  16. Sub-studies 3 and 4: Composite complete remission (CRc)

    To assess CRc

    Time frame: For at least 12 months following discontinuation of treatment

  17. Sub-study 3: Duration of response (DOR)

    To assess the DOR, defined as the duration of CR

    Time frame: For at least 12 months following discontinuation of treatment

  18. Sub-studies 3 and 4: Overall survival (OS)

    To assess overall survival

    Time frame: For at least 12 months following discontinuation of treatment

  19. Sub-studies 3 and 4: Event-free survival (EFS)

    To assess event-free survival

    Time frame: For at least 12 months following discontinuation of treatment

  20. Sub-study 4: Transfusion independence (TI)

    To assess transfusion independence

    Time frame: For at least 12 months following discontinuation of treatment

  21. Sub-studies 3 and 4: Overall response rate (ORR) measurable residual disease (MRD) negativity

    To assess the ORR MRD negativity

    Time frame: For at least 12 months following discontinuation of treatment

  22. Sub-study 4: Number of patients that experience Adverse Events (AEs) and Serious Adverse Events (SAEs)

    Assessed by NCI-CTCAE v5.0

    Time frame: During treatment and up to approximately 28 days after treatment discontinuation, or until immediately before the initiation of another anticancer therapy, whichever occurs first.

  23. Sub-study 4: Duration of response (DOR)

    To assess the DOR, defined as the duration of CR/CRh

    Time frame: For at least 12 months following discontinuation of treatment

  24. Sub-study 4: Time to observed maximum plasma concentration (Tmax) of ziftomenib

    Tmax of ziftomenib and its metabolites

    Time frame: Postdose on Cycle 1 Day 1 and Cycle 2 Day 1. Predose on Cycle 2 onwards

  25. Sub-study 4: Area under the plasma concentration-time curve from time 0 to time t (AUC0-t) of ziftomenib

    AUC0-t of ziftomenib and its metabolites

    Time frame: Postdose on Cycle 1 Day 1 and Cycle 2 Day 1. Predose on Cycle 2 onwards

  26. Sub-study 4: Maximum plasma concentration (Cmax) of ziftomenib

    Cmax of ziftomenib and its metabolites

    Time frame: Postdose on Cycle 1 Day 1 and Cycle 2 Day 1. Predose on Cycle 2 onwards

07

Study locations

43 sites
08

References and documents

Publications

  • Wang ES, Montesinos P, Foran J, Erba H, Rodriguez-Arboli E, Fedorov K, Heiblig M, Heidel FH, Altman JK, Baer MR, Ades L, Pettit K, Peterlin P, Papayannidis C, Berthon C, Walter RB, Shah MV, Balasubramanian S, Khawandanah M, Salamero Garcia O, Bergeron J, Madanat YF, Roboz GJ, Ulrickson M, Redner RL, McCloskey J, Pigneux A, de la Fuente Burguera A, Mitra A, Soifer HS, Tabachri M, Zhang Z, Riches M, Corum D, Leoni M, Issa GC, Fathi AT; KOMET-001. Ziftomenib in Relapsed or Refractory NPM1-Mutated AML. J Clin Oncol. 2025 Nov;43(31):3381-3390. doi: 10.1200/JCO-25-01694. Epub 2025 Sep 25. PubMed 40997296 ↗
  • Wang ES, Issa GC, Erba HP, Altman JK, Montesinos P, DeBotton S, Walter RB, Pettit K, Savona MR, Shah MV, Kremyanskaya M, Baer MR, Foran JM, Schiller G, Ades L, Heiblig M, Berthon C, Peterlin P, Rodriguez-Arboli E, Salamero O, Patnaik MM, Papayannidis C, Grembecka J, Cierpicki T, Clegg B, Ray J, Linhares BM, Nie K, Mitra A, Ahsan JM, Tabachri M, Soifer HS, Corum D, Leoni M, Dale S, Fathi AT. Ziftomenib in relapsed or refractory acute myeloid leukaemia (KOMET-001): a multicentre, open-label, multi-cohort, phase 1 trial. Lancet Oncol. 2024 Oct;25(10):1310-1324. doi: 10.1016/S1470-2045(24)00386-3. PubMed 39362248 ↗
  • Sasca D, Guezguez B, Kuhn MWM. Next generation epigenetic modulators to target myeloid neoplasms. Curr Opin Hematol. 2021 Sep 1;28(5):356-363. doi: 10.1097/MOH.0000000000000673. PubMed 34267079 ↗
  • Jimenez JA, Apfelbaum AA, Hawkins AG, Svoboda LK, Kumar A, Ruiz RO, Garcia AX, Haarer E, Nwosu ZC, Bradin J, Purohit T, Chen D, Cierpicki T, Grembecka J, Lyssiotis CA, Lawlor ER. EWS-FLI1 and Menin Converge to Regulate ATF4 Activity in Ewing Sarcoma. Mol Cancer Res. 2021 Jul;19(7):1182-1195. doi: 10.1158/1541-7786.MCR-20-0679. Epub 2021 Mar 19. PubMed 33741715 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2019 (actual). Primary completion is estimated for Oct 2028, 109 months after the start.

Of 92 industry-sponsored phase 1/2 interventional studies under Leukemia, Myeloid, Acute, half reached primary completion within 73 months of starting (the median), counting those still running; a quarter within 45 and three quarters within 91. This study's planned 109 months is above that.

Counting every sponsor, half of 226 studies reached it within 73 months; a quarter within 48 and three quarters within 106.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 25, 2019
First posted
Aug 26, 2019
StartActual
Sep 12, 2019
Primary completionEst.
Oct 16, 2028
CompletionEst.
Oct 16, 2028
Last update
May 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04067336
Lead sponsor
Kura Oncology, Inc.
Responsible party
Sponsor
First posted
Aug 26, 2019
Start date
Sep 12, 2019
Primary completion
Oct 16, 2028 (estimated)
Completion
Oct 16, 2028 (estimated)
Last update
May 13, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ziftomenib

Start the discussion